• Vanessa Buatois, Laurence Chatel, Laura Cons, Sabrina Lory, Françoise Richard, Florence Guilhot, Zoë Johnson, Claudia Bracaglia, Fabrizio De Benedetti, Cristina de Min, Marie H Kosco-Vilbois, and Walter G Ferlin.
• Novimmune S.A., Plan-les-Ouates, Switzerland. Electronic address: vbuatois@novimmune.com.
• Transl Res. 2017 Feb 1; 180: 37-52.e2.

AbstractLife-threatening cytokine release syndromes include primary (p) and secondary (s) forms of hemophagocytic lymphohistiocytosis (HLH). Below detection in healthy individuals, interferon γ (IFNγ) levels are elevated to measurable concentrations in these afflictions suggesting a central role for this cytokine in the development and maintenance of HLH. Mimicking an infection-driven model of sHLH in mice, we observed that the tissue-derived levels of IFNγ are actually 500- to 2000-fold higher than those measured in the blood. To identify a blood biomarker, we postulated that the IFNγ gene products, CXCL9 and CXCL10 would correlate with disease parameters in the mouse model. To translate this into a disease relevant biomarker, we investigated whether CXCL9 and CXCL10 levels correlated with disease activity in pediatric sHLH patients. Our data demonstrate that disease control in mice correlates with neutralization of IFNγ activity in tissues and that the 2 chemokines serve as serum biomarkers to reflect disease status. Importantly, CXCL9 and CXCL10 levels in pediatric sHLH were shown to correlate with key disease parameters and severity in these patients. Thus, the translatability of the IFNγ-biomarker correlates from mouse to human, advocating the use of serum CXCL9 or CXCL10 as a means to monitor total IFNγ activity in patients with sHLH.Copyright © 2016 Elsevier Inc. All rights reserved.

25 keywords...

hide…